TY  - JOUR
AU  - Harvey, Sandra L
AU  - Khasraw, Mustafa
PY  - 2013
TI  - Alternative targeted therapy for early HER2 positive breast cancer
JF  - Gland Surgery; Vol 2, No 1 (February 04, 2013): Gland Surgery
Y2  - 2013
KW  - 
N2  - Her2 (erbB2) receptor is overexpressed in around twenty percent of early breast cancer and historically conferred a poorer prognosis (1). Targeted anti-Her2 therapy has significantly improved outcomes for these women.
UR  - https://gs.amegroups.org/article/view/1598